New York, 25 September 2025 — A once-distant dream of stopping HIV with a simple injection is now on the verge of becoming reality for millions of people in low- and middle-income countries. Under a landmark partnership announced this week, injectable Lenacapavir will be available from 2027 at an annual cost of $40 across 120 countries. The deal brings together Dr. Reddy’s Laboratories, Unitaid, the Clinton Health Access Initiative (CHAI), and Wits RHI. Originally developed by Gilead Sciences, Lenacapavir is a twice-yearly injection that has demonstrated exceptional effectiveness in preventing HIV. It could transform the landscape of prevention, especially for people who struggle with the burden of taking daily oral PrEP pills.